Download presentation
Presentation is loading. Please wait.
1
European Urology Oncology
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer Niranjan J. Sathianathen, Fernando Alarid-Escudero, Karen M. Kuntz, Nathan Lawrentschuk, Damien M. Bolton, Declan G. Murphy, Simon P. Kim, Badrinath R. Konety European Urology Oncology DOI: /j.euo Copyright © 2019 European Association of Urology Terms and Conditions
2
Fig. 1 Cost-effectiveness acceptability curve showing the probability that a treatment represents the most cost-effective strategy at a particular willingness-to-pay threshold. QALY=quality-adjusted life year. European Urology Oncology DOI: ( /j.euo ) Copyright © 2019 European Association of Urology Terms and Conditions
3
Fig. 2 Incremental cost-effectiveness scatter plot of 5000 simulations demonstrating a low to moderate probability of abiraterone acetate (AA) plus androgen deprivation therapy being cost-effective even at willingness-to-pay thresholds beyond those that are commonly accepted. A point has to be to the right and below the willingness-to-pay threshold line to be cost-effective. European Urology Oncology DOI: ( /j.euo ) Copyright © 2019 European Association of Urology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.